AaronLEllenbogenDO

Movement Disorder

Neurologist in Farmington, Michigan and is affiliated with multiple hospitals in the area, including Beaumont Hospital-Farmington Hills and Beaumont Hospital-Troy

Join to view full profile

Dr. Ellenbogen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ellenbogen's full profile

Already have an account?

Office
28595 Orchard Lake Rd
Ste 200
Farmington Hills, MI 48334
Phone+1 248-553-0010

Fax+1 248-553-5957

Education & Training

Michigan State University College of Osteopathic MedicineClass of 1998

Certifications & Licensure

MI State License 1999 - 2025
AOA Board of Neurology and Psychiatry Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2013

Clinical Trials

Study of SPARC1103 in Subjects With Spasticity Start of enrollment: 2014 Apr 21
Completed
Phase 2
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease Start of enrollment: 2014 Jun 01
Completed
Phase 1
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease Start of enrollment: 2016 Nov 30
Completed
Phase 2

Publications & Presentations

PubMed

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study.
Aaron L Ellenbogen, Werner Poewe, Alberto J Espay, Tanya Simuni, Tanya Gurevich
Parkinsonism & Related Disorders. 2025-01-16
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.
Nicola L Brice, Mark Carlton, David H Margolin, Martin Bexon, Kim L Matthews
Eclinicalmedicine. 2024-11-01
Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information.
Khashayar Dashtipour, Han S Lee, Aaron Ellenbogen, Rashid Kazerooni, Todd M Gross
Toxins. 2024-10-15

Journal Articles

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinica...
Jankovic J1, Goodman I2, Safirstein B3, Marmon TK4, Schenk DB4, Koller M4, Zago W4, Ness DK4, Griffith SG5, Grundman M6,7, Soto J4, Ostrowitzki S8, Boess FG9, Martin-F..., JAMA Neurology, 10/2018

Press Mentions

Two Early Symptoms of Parkinson’s Disease Were Discovered. They Are Not ClearApril 4th, 2022
Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s PatientsSeptember 1st, 2017
Alcanza’s Quest Research Institute Advocates Awareness and Education During Parkinson’s Disease Awareness Month; Provides Updates on Recent Parkinson’s Disease ResearchApril 27th, 2024